Review places orforglipron between semaglutide and tirzepatide on weight loss

The wire

1. 01The review covered two phase 1 studies and four phase 2/3 obesity trials of orforglipron, finding mean placebo-adjusted weight reduction of 7.1% to 10.6%, with mainly gastrointestinal adverse events.
2. 02Authors position orforglipron as potentially more effective than liraglutide, similar to semaglutide and less effective than tirzepatide, with no strict oral administration requirements.
3. 03They note the drug still lacks data on efficacy in obesity-related comorbidities, limiting head-to-head comparison with established agents.

From the source

Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment

The Annals of pharmacotherapy · 2026 Sep 18 · Wietholter JP, Terpening CM et al.